Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2106 vs Tremfye in Healthy Subjects
NCT07479576Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL2106 in plaque psoriasis (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Pharmacokinetics. Started Nov 2025; status: completed.
02
Drugs
QL2106
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07479576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479576.